<DOC>
	<DOC>NCT02531815</DOC>
	<brief_summary>This Phase 1 first-in-human single ascending dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086.</brief_summary>
	<brief_title>Dose Escalation Study of PF-06741086 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs) and 100 kg (220 lbs). Increased risk of thrombosis (coronary artery disease, hypercholesterolemia, diabetes) Use of nicotine/tobacco products Clotting disorders</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Phase 1</keyword>
	<keyword>first in human</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>tissue factor pathway inhibitor</keyword>
	<keyword>japanese</keyword>
</DOC>